RESEARCH ARTICLE

Public trust and genomic medicine in Canada and the UK

[version 1; peer review: 2 approved, 1 approved with reservations]

Sarah Savić-Kallesøe ¹, Anna Middleton ^{2,3}, Richard Milne ^{1,2}

¹Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB2 0SR, UK

²Society and Ethics Research, Wellcome Connecting Science, Cambridge, CB10 1SA, UK

³Faculty of Education, University of Cambridge, Cambridge, CB2 8PQ, UK

V1 First published: 20 May 2021, 6:124
<https://doi.org/10.12688/wellcomeopenres.16831.1>
 Latest published: 01 Jul 2021, 6:124
<https://doi.org/10.12688/wellcomeopenres.16831.2>

Abstract

Background: Genomic medicine could improve precise risk stratification, early prevention, and personalised treatment across a broad spectrum of disease. As this reality approaches, questions on the importance of public trust arise. The success of genomic medicine initiatives is influenced by the public's trust and willingness to engage. Specific social actors influential in the public's trust have been identified by the "Your DNA, Your Say" study, including doctors, researchers, and governments. This paper aims to identify and examine which specific social actors, if any, in Canada and the United Kingdom (UK) are the most trustworthy and influential to engage the public in genomic medicine.

Methods: Using data from the 'Your DNA, Your Say' study, logistic regression models and Pearson's chi-square tests were conducted to explore trust in social actors across Canada and the UK.

Results: The results demonstrate Canada and the UK significantly differ in public trust and willingness to donate. Non-profit researchers, domestic doctors, and personal doctors were identified to be the most influential and trustworthy social actors in Canada and the UK.

Conclusions: The comparative results indicate that both countries would benefit from engaging the public through doctors and non-profit researchers. The UK could additionally support public trust by engaging with the public through the National Health Service. However, the results suggest that whilst public trust is significant, it may be neither necessary nor sufficient in influencing willingness to donate. Future research could do well to investigate how the importance of public trust compares in countries with lower public trust.

Keywords

genomics, public trust, data sharing, Canada, United Kingdom, personalised medicine, personalized medicine, genomic medicine

Open Peer Review

Approval Status

	1	2	3
version 2			
(revision)			
01 Jul 2021		view	view
version 1			
20 May 2021	view	view	view

1. **Ruth Horn**, University of Oxford, Oxford, UK

2. **Alessandro Blasimme** , ETH Zürich, Zürich, Switzerland

3. **Mavis Machirori**, Ada Lovelace Institute, London, UK

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Richard Milne (richard.milne@wellcomeconnectingscience.org)

Author roles: Savić-Kallesøe S: Conceptualization, Formal Analysis, Software, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Middleton A: Funding Acquisition, Investigation, Methodology, Project Administration; Milne R: Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Wellcome Trust [206194].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Savić-Kallesøe S *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Savić-Kallesøe S, Middleton A and Milne R. **Public trust and genomic medicine in Canada and the UK [version 1; peer review: 2 approved, 1 approved with reservations]** Wellcome Open Research 2021, 6:124 <https://doi.org/10.12688/wellcomeopenres.16831.1>

First published: 20 May 2021, 6:124 <https://doi.org/10.12688/wellcomeopenres.16831.1>

Introduction

Genomic medicine and public health

The sharing of patient data, especially genomic data, across a healthcare system is pertinent for the improvement of population screening and patient care. Broadly defined, genomic data refers to an individual's sequenced DNA¹. Genomic medicine, a subset of precision medicine, pertains to using an individual's genomic data to guide clinical care, including screening, diagnostics, and treatments². Medical information includes individuals' demographic profile and medical history of diagnostics, diseases, and treatments³.

At the population level, genomic medicine may revolutionize how we identify and care for populations at high-risk for an array of diseases. A key public health implication of genomic medicine is population risk stratification based on genetic predisposition, allowing for earlier, more precise, and more cost-effective intervention⁴ and the potential to improve population screening for a spectrum of diseases. Genomic medicine integrated into routine healthcare would afford patients robust disease risk prediction, improved precision and positive predictability value of diagnostics, and medication regimes tailored to their genetic profile⁵.

Integrating genomic medicine into routine healthcare involves collecting, storing, and analyzing data from the genomes of a large number of individuals. Consequently, many countries have pledged to utilize genomic medicine into healthcare through large-scale sequencing initiatives involving at least 100,000 citizens, including the UK, Saudi Arabia, Turkey, France, and the United States (which aims to sequence a million genomes)⁶.

Public trust

The success of genomic medicine depends on the willingness of the public, as patients and non-patients, to make genomic and health information about themselves available to others. A key factor in this is people's trust in the government's and healthcare system's ability to securely store, disseminate, and analyze data. While difficult to measure, evidence suggests that public trust in government in Anglo-Saxon countries, including the US, Canada, and the UK, has been generally declining⁷.

In the UK, the 'care.data' initiative announced in 2013 was meant to facilitate health service and provision planning by extracting and pooling patient data from general practitioner offices into a national database^{8,9}. The default 'opt-out' of the programme, which required action to withdraw consent, was met with controversy and public disapproval^{9,10}. The care.data initiative was abandoned in 2014, which was largely attributed to its failure to gain the confidence of patients, healthcare professionals, and citizens in its procurement of consent and management of data.

Canada faces systemic barriers in patient data sharing, largely due to its decentralized structure; instead of a single national healthcare system, there are 10 provincial, three territorial, and one federal healthcare systems, each providing care for different groups of people, typically based on region¹¹. Each

system is the sole owner of its health-related data, including surveillance and patient data¹². Currently, there is no pan-Canadian electronic medical data system, whereby a patient's data is accessible anywhere in the nation¹³. This results in patients carrying the burden of recording their medical history and presenting it to each new health professional they encounter. However, the lack of successful cooperation between entities results in a patchwork of electronic medical record systems and contributes to patient burden, as well as fading trust in Canada's healthcare^{7,14,15}.

Failed implementations such as this demonstrate the importance of public trust in the success of public health initiatives. The influence of the public's trust was also evident in the 2009 H1N1 pandemic, when hampered vaccine uptake was attributed to distrust in government and the scientific community, vocalised by groups such as anti-vaccine followings¹⁶. Similarly, the efficacy of large scale lockdowns instated during COVID-19 to prevent the transmission of SARS-CoV-2 was attenuated as public trust and compliance wavered^{17,18}.

Public confidence in institutional healthcare is also crucial for effective routine patient-doctor relationships. There is evidence indicating that trust in institutional healthcare, such as hospitals and insurance providers, affects individual's willingness to access care¹⁷. There is evidence of a general lack of trust between the public and healthcare system, which may make it more difficult to integrate personal information into routine clinical care^{19,20}. In addition, marginalised populations facing systemic bias and who may have personal experience with discrimination may develop distrust in institutions and, consequently, access health services disproportionately less¹⁷. This is reflected in inequitable outcomes, such as poor adherence to recommendations and worse self-reported health, among marginalised communities^{21–24}.

Fostering public trust in genomic medicine poses additional challenges compared to those of other public health initiatives. These differences include that the implications of genomic data extend beyond the patient and to their biological relatives²⁵. Additionally, due to its identifiable nature, DNA information may require exceptional protection²⁵. For these reasons, the integration of genomic medicine into mainstream healthcare must be purposefully and thoughtfully informed by the public voice. At the core of its successful integration is a trusting relationship between the public and the healthcare system.

Canada and the UK

The "Your DNA, Your Say" (YDYS) study aims to understand the public's inclination to participate in data sharing based on their willingness to donate their DNA information; it has identified willingness to donate DNA to be related to general public trust in social actors, such as the government, non-profit researchers, and doctors across 22 countries^{26,27}. Prior publications have investigated how trust and willingness to donate trend across the 22 countries, and have examined the Anglo-Saxon countries as a cluster. These analyses suggest that the public's trust plays a key role in the population's willingness

to donate DNA; across all countries examined in the YDYS study, overall trust was found to be positively associated with willingness to donate²⁸. This trend is also evident within the grouped analysis of Canada, the USA, Australia and the UK²⁶.

Previous analyses of YDYS data indicated that Canada and the UK have similarly influential social actors in relation to health data²⁶. This could be linked to their structurally similar universal healthcare systems and deep shared historical ties. Given this, we would expect that Canada and the UK would have similar results in public trust and willingness to donate DNA information. Indeed, further analyses have suggested that Canada and the UK may be particularly closely related in terms of how respondents perceive the trustworthiness of data institutions^{28,29}. In this paper we investigate which social actors, if any, in Canada and the UK are the most trusted and may be most influential to effectively engage the public in genomic medicine. We develop a comparative analysis of the UK and Canada to understand the nuances of the public's trust in social actors involved in genomic medicine and patient data sharing, such as the government, doctors, and the healthcare system. The implications of such findings would contribute to the evidence base for future informed patient data sharing initiatives.

Objectives

The YDYS study is the source of data for this paper, which includes survey responses from 36,268 individuals across 22 countries, collected from 2017 and onwards. The purpose of the YDYS study is to assess: the public's attitudes and trust towards donating and sharing of genomic information; the characteristics of those most and least willing to donate; the characteristics of those most and least trusting of government and medical social actors. The research question posed in this paper is "Are there differences in public trust between Canada and the UK and might they affect the public's willingness to donate DNA information for genomic medicine research?" Considering that the data are cross-sectional and ecological in nature, this investigation is meant to be hypothesis-generating and exploratory rather than conclusive.

Specifically, this paper aims to:

1. Compare proportions of the public's trust in and the influences of social actors in willingness to donate between Canada and the UK.
2. Assess whether these differences in public trust warrant separate tailored strategies in engaging the public genomic medicine.
3. Identify potential structures that could explain the variation in public trust and willingness to donate between Canada and the UK.

Methods

Data from the YDYS study were used for this paper, the methodological details of which have been published separately³⁰. Responses from 36,268 participants were collected through

an online survey available in 14 languages across 22 countries. Of those, 2,961 participants were in Canada and 3,406 in the UK, totalling 6,373 participants. Responses were collected by a market research company, Dynata, in 2017. The samples are evaluated to be representative, based on comparisons with national census data of population age and gender structure. Participants were offered a small financial incentive (< £1). The recruitment method did not allow for a known non-response rate. Consisting of 29 questions, the survey³¹, which can be accessed at YourDNAYourSay.org, takes approximately 15–20 minutes to complete.

Measure definitions

Trust. Participants' overall trust and trust in specific social actors were both assessed. Participants were asked whether they generally trust the following social actors: their doctor, any domestic doctor, any international doctor, their country's government, for-profit researchers, and non-profit researchers. Non-profit researchers included university and publicly funded researchers. For-profit researchers included researchers funded by private companies spanning across a wide scope of industries, such as pharmaceutical, drug discovery, diagnostic, and healthcare technology development. Response options included "Yes", "No", and "Unsure". The "No" and "Unsure" responses were combined for analysis, reflecting the active choice nature of trust discussed above, our interest in investigating the influence of active trust on willingness to donate and to improve the statistical power of tests drawing on respondents who did not actively trust. Participants were defined as "generally trusting" if they reported "Yes" to trusting at least two social actors. In our analysis, we treat trust in certain social actors as proxies for trust in the national healthcare system (trust in any domestic doctor) and trust in the medical profession (any international doctor).

Willingness to donate DNA. Participants were categorised as generally willing to donate if they self-reported willing to donate to at least two of the following: medical doctors, for-profit researchers, or non-profit researchers. Those who did not were categorised as not generally willing to donate.

Familiarity with genetics. Participants self-reported whether they were familiar with DNA, genetics, or genomics. Those who reported familiarity were asked for further detail, and those with knowledge of DNA through family or personal medical history or their work (i.e. genetics counsellor, genetic researcher, etc.) were identified as having 'personal familiarity'. Those who did not identify being familiar with genetics were categorised as 'unfamiliar'.

DNA status. Participants were asked whether they regard DNA information to be different from other medical information. Participants were categorised as either regarding DNA information different from other medical information, the same, or unsure. For analysis, 'same' and 'unsure' responses were combined as we are interested in investigating those who see DNA information as different.

Analysis

The statistical software Stata, version 16.1, was used to clean the data and conduct analysis. A logistic regression model was created to explore whether public trust is influential in willingness to donate DNA. Pearson's chi-squared tests were performed to identify whether there were statistical differences in the proportions of those willing to donate DNA information or of those who are overall trusting between Canada and the UK. Two logistic regression models, one for each country, were created to investigate how social actors and other factors might influence willingness to donate in Canada and the UK. Factors included familiarity of genetics, perception of DNA information as different from other medical information, and trust in specific social actors. Social actors included the respondent's doctor, any domestic doctor, any international doctor, their country's government, a for-profit researcher, and non-profit researcher. Social actors with discordant significance between the country models were further investigated by chi-square tests, exploring whether Canada and the UK significantly differ in proportions who trust these social actors, including doctors and for-profit researchers.

Ethics

The online survey is fully anonymous. Participants are informed that their consent is given when they choose to click off the landing page and start answering the questions. On the landing page, the purpose of the project is explained as well as what participation involves; participants have a choice at any stage within the survey to stop answering the questions and withdraw. The online project is physically based at the Wellcome Genome Campus with all data collected and stored in encrypted files at the Wellcome Sanger Institute in Cambridge. As part of the conditions of research delivery at this research institution, the project passed ethical review by the Human

Materials and Data Management Committee of the Wellcome Sanger Institute (Registration Number: 16/029), as well as legal review to ensure that it was compliant with ethical and legal standards for participant involvement, data collection, and storage.

Results

Trust and willingness to donate DNA

As mentioned in the introduction, existing literature has identified a positive association between overall trust and willingness to donate genomic data within Canada and the UK. Pooling the Canadian and UK samples, the logistic regression model in [Table 1](#) suggests that overall trust is significantly associated with willingness to donate; the odds that an individual willing to donate to generally be trusting of social actors is 4.61 times more likely than not generally trusting (95% CI, 4.13-5.15) ([Table 1](#)). In both countries almost half of Canadian and UK respondents report general trust in multiple potential data users (Canada: 48.56%; UK: 53.82%)³¹.

Comparing Canada and the UK

Chi-square tests were conducted to compare how Canada and the UK differ in willingness to donate DNA and trust ([Table 2](#)). The results indicate there to be a significant difference in overall trust between Canada (48.56%) and the UK (53.82%) ([Table 2](#)). A significantly greater proportion of the Canadian sample (45.96%) was willing to donate compared to the UK (40.49%). Considering there are significant differences in the degree of trust, logistic regression models were developed to investigate the influences of trust on willingness to donate in the Canadian and UK samples separately ([Table 3](#)).

Separate logistic regression models were created for the Canadian and UK samples ([Table 3](#)). Terms predicting willingness

Table 1. Logistic regression: Trust and willingness to donate DNA (pooled).

Canada and the UK (n = 6,367)			
Willing to donate:	Odds ratio	P	95% Confidence interval
Are generally trusting* (Ref = not trusting or unsure)	4.61	0.000	(4.13 – 5.15)
Familiar with genetics (Ref = no familiarity with genetics)	1.97	0.000	(1.76 – 2.21)
Regard DNA as different from other medical information (Ref = regarding medical and DNA information to be the same)	1.53	0.000	(1.37 – 1.71)
Country (Ref = Canada)	0.75	0.000	(0.67 – 0.83)
Constant	0.24	0.000	(0.21 – 0.27)

* Defined as participants who trust at least two of the following: their doctor, any domestic doctor, their country's government, domestic for-profit researchers, or domestic non-profit researchers.

Table 2. Differences in public trust and willingness to donate in Canada and the UK.

Participants who:	Canada (n = 2,961)		United Kingdom (n = 3,406)		P
	N	%	N	%	
Are generally trusting*	1,438	48.56	1,833	53.82	0.000
Are willing to donate DNA	1,361	45.96	1,379	40.49	0.000
Trust their doctor	2,276	76.87	2,638	77.45	0.579
Trust any domestic doctor	1,054	35.60	1,597	46.89	0.000
Trust any international doctor	422	14.25	548	16.09	0.042
Trust non-profit researchers	1,110	37.49	1,124	33.00	0.000
Trust for-profit researchers	345	11.65	330	9.69	0.011
Trust their country's government	570	19.25	558	16.38	0.003

* Defined as participants who trust at least two of the following: their doctor, any domestic doctor, their country's government, domestic for-profit researchers, or domestic non-profit researchers.

Table 3. Logistic regression models: Trust and willingness to donate DNA.

Willing to donate:	Canada (n = 2,961)			United Kingdom (n = 3,406)		
	Odds ratio	P	95% Confidence interval	Odds ratio	P	95% Confidence interval
Trust their doctor	1.78	0.000	(1.43 – 2.21)	1.97	0.000	(1.56 – 2.48)
Trust any domestic doctor	1.53	0.000	(1.24 – 1.87)	1.38	0.001	(1.15 – 1.66)
Trust any international doctor	1.16	0.297	(0.87 – 1.55)	1.13	0.296	(0.90 – 1.44)
Trust non-profit researchers	3.38	0.000	(2.79 – 4.08)	3.91	0.000	(3.26 – 4.69)
Trust for-profit researchers	1.17	0.000	(1.27 – 2.34)	1.31	0.079	(0.97 – 1.78)
Trust their country's government (Ref = not trusting or unsure)	1.47	0.001	(1.17 – 1.86)	1.58	0.000	(1.25 – 1.98)
Familiar with genetics (Ref = no familiarity with genetics)	1.72	0.000	(1.46 – 2.04)	2.04	0.000	(1.73 – 2.40)
Regard DNA as different from other medical information (Ref = regarding medical and DNA information to be the same)	1.42	0.000	(1.20 – 1.68)	1.53	0.000	(1.31 – 1.79)
Constant	0.17	0.000	(0.14 – 0.21)	0.12	0.000	(0.09 – 0.14)

to donate included trust in: one's doctor, any domestic doctor, any international doctor, the country's government, for-profit researchers, non-profit researchers; familiarity with genetics; and whether they saw DNA information as different from other medical information. All terms were significantly associated with willingness to donate in both country models, except for trust in any international doctor, which was not

significant in either country's model (Canada: OR 1.16, 95% CI 0.87-1.55; UK: OR 1.13, 95% CI 0.90-1.43). Trust in domestic doctors was found to be influential in willingness to donate DNA in both countries (Table 3); the odds of a willing Canadian to be trusting of any domestic doctor are 1.53 times than to not be willing to donate (95% CI 1.24-1.87) and 1.97 times for a willing individual in the UK (95%

CI 1.56-2.48). Trust in for-profit researchers was found to be significant in predicting willingness to donate in the Canadian model (OR 1.73, 95% CI 1.27-2.34) but not the UK model (OR 1.31, 95% CI 0.97-1.78). Doctors and for-profit researchers were of particular interest, suggesting they may contribute to differences in trust and willingness to donate between Canada and the UK.

Doctors. The proportions of those who trust their doctor, any doctor, and any international doctor were compared between Canada and the UK (Table 2). Personal doctors hold the highest level of public trust and there is no evidence to suggest that the proportions differ significantly between Canada (76.87%) and the UK (77.45%). The regression models in Table 3 suggest that trust in any domestic doctor is a significant explanatory variable in both Canada and the UK. However, the chi-square results suggest that a significantly greater proportion of the UK sample (46.89%) trust any domestic doctor compared to the Canadian sample (35.60%). Trust in international doctors was not a significant explanatory variable in either model and there was no evidence to suggest there to be a difference in the proportions who trust them between Canada and the UK (Canada: 14.25%; UK: 16.09%).

A chi-square test was run to assess differences in the proportion who trust in their doctor (Table 4). The oldest group, over 60 years, had significantly higher proportions of trust. Significant differences were also found in trusting domestic doctors across age in the Canadian sample ($P=0.003$) (Table 4); the age category with the greatest trust in domestic doctors

is the 31–40-year group (40.10%). No significant differences were found in trusting domestic doctors across age categories in the UK sample ($P=0.089$).

For-profit researchers. Trust in for-profit researchers was significant in willingness to donate in Canada but not the UK (Table 3). This discordance of significance was further assessed with chi-square tests and comparisons to trust in non-profit researchers. In both Canada and the UK, the proportion who trust non-profit researchers (Canada: 37.49%; UK: 33.0%) is significantly greater than the proportion who trust for-profit researchers (Canada: 11.65%; UK: 9.69%) (Table 2). However, these proportions who trust either for-profit or non-profit researchers differ significantly between Canada and the UK.

Discussion

Identifying social actors who hold the greatest public trust and influence has the potential to support the success of genomic medicine and data sharing initiatives, consequently improving the precision of population risk stratification, earlier preventative care, and, consequently, lightening healthcare burdens. The paper has aimed to understand the nuances in the public's trust of social actors in Canada and the UK, two countries with relatively high levels of public trust that previous analyses have suggested are similar. Doctors and for-profit researchers were identified to be of interest in the logistic regression models.

Existing YDYS publications suggest overall trust in social actors to be influential in one's willingness to donate. Considering that the proportions who generally trust social actors

Table 4. Differences in trust in doctors across age groups in Canada and the UK.

	Canada (n = 2,961)			United Kingdom (n = 3,406)		
Those who trust their doctor:	N	n	%	N	n	%
30 years and under	451	631	71.47	702	912	76.97
31 – 40 years	452	606	74.59	504	690	73.04
41 – 50 years	404	528	76.52	476	619	76.90
51 – 60 years	447	567	78.84	462	588	78.57
Over 60 years	522	629	82.99	494	597	82.75
	$P = 0.000$			$P = 0.001$		
Those who trust any domestic doctor:	N	n	%	N	n	%
30 years and under	236	631	37.40	460	912	50.44
31 – 40 years	243	606	40.10	324	690	46.96
41 – 50 years	198	528	37.50	289	619	46.69
51 – 60 years	181	567	31.92	258	588	43.88
Over 60 years	196	629	31.16	266	597	44.56
	$P = 0.003$			$P = 0.089$		

significantly differ between Canada (48.56%) and the UK (53.82%), the UK sample was expected to have a higher proportion of those willing to donate (Table 2). Contrary to expectation, the results suggest that the UK sample has a smaller proportion of participants willing to donate (40.49%) compared to the Canadian sample (45.96%) (Table 2).

The Canadian sample displays a significantly higher degree of willingness to donate and trust in researchers. Personal doctors hold the highest degree of public trust, followed by non-profit researchers. Trust in personal doctors varies across age, with a greater proportion of older patients (60 years and above) trusting their doctor. Similar to the UK sample, trust in non-profit researchers appears to have the strongest association with willingness to donate. Based on this evidence, personal doctors and non-profit researchers are the most influential and trustworthy social actors with regards to encouraging the public to donate genomic information for medical research in Canada.

In the UK sample, a significantly greater proportion were generally trusting, trust their own doctor, and trust any domestic doctor, suggesting a strong degree of public trust in the healthcare system. A trend of trust in personal doctors was observed, with the oldest participants (>60 years) displaying the greatest proportion who trust in their doctor. A similar trend in trust for domestic doctors was not found, with no particular age group displaying a significantly different level of trust. Similar to the Canadian sample, trust in non-profit researchers among the UK participants has the greatest association with willingness to donate. However, unlike its Canadian counterpart, trust in for-profit researchers was not found to be significantly associated with willingness to donate.

Trust in doctors

Trust in three types of doctors were investigated, each representing a different relation with the public. We can understand participants' trust in any domestic doctors as reflecting their overall trust in the country's healthcare system, while trust in any international doctor might be understood as a proxy of their trust in the medical profession.

In Canada and the UK, an individual's own doctor holds influential power on participants' willingness to donate and the highest degree of trust. Trust in international doctors was not found to be influential in willingness to donate in either country. Trust tends to attenuate as social relationships become more distant³², so it is expected that personal doctors would hold greater trust compared to domestic doctors, and for domestic doctors to hold more trust compared to international doctors. The proportions who trust doctors in Canada and the UK are similar, except for trust in domestic doctors; while public trust in domestic doctors is influential in both samples, it is significantly higher in the UK. With regards to the degree of influence on participants' willingness to donate, personal, domestic, and international doctors held similar levels of influence between Canada and the UK.

Variation across age. Trust in personal doctors significantly varies across age. The age group with the greatest proportion trusting one's doctor is the oldest group (>60 years), in

both Canada and the UK, which is consistent with the positive association between age and trust in doctors previously identified³³. Variation in trust across age also exists amongst domestic doctors; the second youngest group (31–40 years) in the Canadian sample had the highest proportion of those who trust domestic doctors, suggesting they may be the most trusting of the healthcare system. However, there was no evidence to suggest a trend across age in the UK sample.

Trust in researchers

Trust in non-profit researchers was found to be the most influential for willingness to donate in Canada and in the UK (Table 3). Yet non-profit researchers were the second most trusted social actor in Canada (following personal doctors and followed by domestic doctors) and third most trusted in the UK (following personal doctors and domestic doctors). The difference between Canada and the UK in relative trust between non-profit researchers and domestic doctors further suggests that the healthcare system holds stronger influence on the willingness to donate DNA in the UK.

The influential role of non-profit researchers in public trust in both countries might be associated with their obligation to safeguard and role in analysing patient data³⁴. Similarly, doctors might hold high trust due to their role in applying genomic data findings to medical recommendations³⁴. The stronger influence of trust in non-profit researchers over personal doctors in both countries might highlight the public's interest in the safeguarding and analysis of their data.

Why is it that trust in non-profit researchers appears more influential in willingness to donate than trust in for-profit researchers? One explanation may be the importance of trust in, and alignment of, motives³⁵. Thus, for non-profit research, which is often founded on principles of altruism or solidarity, it may be more important that there is a perceived alignment of values between the research population and the researcher. The donation of data to non-profit researchers, relies on faith that non-profit researchers will act in the interests of the public good. Conversely, a general lack of public trust and engagement has been observed for for-profit research initiatives that use patient data, yet trust seems less influential in shaping the willingness to donate to these actors^{36,37}.

These findings suggest that, in the development of public genomic medicine initiatives, value alignment between social actors and the public is influential. Moreover, trustworthiness of these initiatives may be reliant on their being guided by non-profit rather than for-profit initiatives.

Implications

The findings presented here have implications for the development of policy and practice in engaging publics with genomic medicine. First among these is the role of doctors and the health system as the interface between the public and genomic medicine initiatives. Doctors are a key social actor and potential leverage point in engaging the public in genomic medicine as they, by professional nature, often act as an interface between the public and the healthcare system. However, there are complications in engaging the public through personal doctors.

The most pertinent being that not everyone has a designated doctor ('family' doctor), and that those who are more disadvantaged are less likely to have a doctor^{33,38}. If engagement methods rely on patients receiving information from their doctor, and if a discrepancy exists in how primary care is accessed, this will systematically disfavour those who are already more disadvantaged. The second consideration is that depending on individual doctors to inform their patients of genomic medicine in addition to their duties within the limited appointment time may be infeasible and burdensome. Lastly, relying on individual doctors to disseminate information will inevitably foster inconsistency; it would also be impractical to guide efforts pursued by individual doctors rather than to steer a single, composite effort by the healthcare system.

Considering that public trust in the healthcare system is a distinguishing feature between Canada and the UK, policy decisions surrounding the implementations of genomic medicine might reflect the social actors that garner the most trust. The UK might best encourage public trust through individual doctor-patient relations and mass-media campaigns carried out by the National Health Service (NHS). Comparatively, Canada might more effectively focus on patients' relationships with personal doctors and with non-profit researchers. This might involve doctors informing patients how their genomic information could affect medical recommendations.

Necessity vs. sufficiency of public trust

However, it is also important to recognise that our findings show that while public trust is influential, it may not always be necessary. The public regularly interacts with social actors with whom they do not share values with or who are not widely trusted. The nuances of trust also raise questions regarding its sufficiency for willingness to donate. The evidence suggests that the Canadian public is generally more trusting of both non-profit and for-profit researchers. This could be explained if the Canadian sample were more generally trusting. However, the Canadian sample has a smaller proportion who trust social actors overall. Whilst counterintuitive, there are likely other factors influencing trust. One important aspect is that trust is far more nuanced than we are able to capture in this study. Trust is associated with increased odds to willingness to donate and there are significant differences in the degrees of trust across Canada and the UK. But, as demonstrated in the results, high levels of public trust do not guarantee high levels of willingness to donate; people are willing to donate even when they don't trust, and it cannot be guaranteed that those who do trust will also be willing to donate. Public trust is not sufficient for willingness to donate. Overall trust may not be determinant in willingness to donate, but trust in the social actors involved in the collection, management, storage, and application of one's genomic information is influential.

Limitations

A key vulnerability of this study is reductionism. Trust is complex, dynamic, and context dependent, making it difficult to reflect through an exploratory quantitative study. Trusting multiple specific social actors does not necessarily equate to having a high level of general trust. This study focused on identifying social actors who hold the public's trust. In the

exploration of active trust, responses indicating distrust and uncertainty were pooled during statistical analysis. By doing so, this study did not identify social actors who harbour active distrust. Further investigations could compare levels of public trust and distrust of social actors. Identifying characteristics that make social actors more or less trustworthy would be pertinent in the implementation of initiatives that rely on high public trust to be effective. Considering there are no previous publications on the topic of public trust and attitudes towards genomic medicine using a global survey, evaluating validity by comparing to similar studies is not feasible. Additionally, using an online survey as the method of data collection is limited in that non-response rates are unknown and populations with poor access to the internet are not represented. Lastly, by nature of this study being of cross-sectional design, the questions posed are exploratory in nature; the results speak only to associations and are not conclusive.

Conclusion

Genomic medicine has the potential to improve precise risk stratification, early prevention, and specialised treatment. However, the public's trust is consequential for its efficacy. The aim of this research was to investigate how Canada and the UK differ in willingness to donate DNA and how willingness is influenced by trust in social actors. Evidence suggests that public trust in Canada and the UK differ enough to justify tailoring separate methods for engaging the public in genomic medicine; the UK could benefit more from a mix of personal doctor and healthcare system engagement, whereas Canada could benefit from a method which focuses on engaging the public through their doctors. Both countries could gain from involving non-profit researchers, as trust in them is the most strongly associated with willingness to donate in both countries. Whilst the evidence suggests that trust may not be necessary nor sufficient in the public's willingness to donate, it also suggests trust is hugely influential. Future research could do well to investigate how the necessity and sufficiency of public trust might vary across countries with low and high overall public trust.

Data availability

Underlying data

Open Science Framework: Your DNA Your Say data file. <https://doi.org/10.17605/OSF.IO/ZPFGM31>.

This project contains the following underlying data:

- YDYS dataset for sharing.csv
- DataDictionary.csv

Extended data

Open Science Framework: Your DNA Your Say data file. <https://doi.org/10.17605/OSF.IO/ZPFGM31>.

This project contains the following extended data:

- Word Version GA4GH Survey.docx

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

References

1. Finnegan T, Hall A: **Identification and Genomic Data**. PHG Foundation; 2017. [Reference Source](#)
2. National Human Genome Research Institute: **Genomics and Medicine**. [genome.gov](#). 2020; Accessed January 13, 2021. [Reference Source](#)
3. Law Insider: **Definition of Medical Information**. Law Insider. Accessed January 13, 2021. [Reference Source](#)
4. Hernandez L: **Implications of Genomics for Public Health**. National Academies Press (US); 2005; Accessed July 26, 2020. [Reference Source](#)
5. Baldovino S, Moliner AM, Taruscio D, *et al.*: **Rare Diseases in Europe: from a Wide to a Local Perspective**. *Isr Med Assoc J*. 2016; **18**(6): 359–63. [PubMed Abstract](#)
6. Philippidis A: **THE 100,000 Genomes Club: 10 Countries Meet the Mark for National Genome Projects**. *Clin OMICS*. 2018; **5**(5): 40–46. [Publisher Full Text](#)
7. van de Walle S, van Roosbroek S, Bouckaert G: **Trust in the public sector: is there any evidence for a long-term decline?** *Int Rev Adm Sci*. 2008; **74**(1): 47–64. [Publisher Full Text](#)
8. van Staa TP, Goldacre B, Buchan I, *et al.*: **Big health data: the need to earn public trust**. *BMJ*. 2016; **354**: i3636. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Carter P, Laurie GT, Dixon-Woods M: **The social licence for research: why care data ran into trouble**. *J Med Ethics*. 2015; **41**(5): 404–409. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Rowe R, Calnan M: **Trust relations in health care—the new agenda**. *Eur J Public Health*. 2006; **16**(1): 4–6. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Government of Canada: **Canada's Health Care System**. Government of Canada. 2016; Accessed January 13, 2021. [Reference Source](#)
12. Attaran A, Houston A: **Pandemic Data Sharing: How the Canadian Constitution Turned Into a Suicide Pact**. Social Science Research Network; 2020. [Publisher Full Text](#)
13. Azarm-Daigle M, Kuziemyk C, Peyton L: **A Review of Cross Organizational Healthcare Data Sharing**. *6th Int Conf Emerg Ubiquitous Syst Pervasive Netw EUSPN 2015 5th Int Conf Curr Future Trends Inf Commun Technol Healthc ICTH-2015 Affil Workshop*. 2015; **63**: 425–432. [Publisher Full Text](#)
14. Heintzman R, Marson B: **People, service and trust: is there a public sector service value chain?** *Int Rev Adm Sci*. 2005; **71**(4): 549–575. [Publisher Full Text](#)
15. Stokes K: **Edelman Trust Barometer 2020 Report: Trust in Canada**. Edelman; 2020; 29. Accessed January 13, 2021. [Reference Source](#)
16. Larson HJ, Heymann DL: **Public Health Response to Influenza A(H1N1) as an Opportunity to Build Public Trust**. *JAMA*. 2010; **303**(3): 271–272. [PubMed Abstract](#) | [Publisher Full Text](#)
17. Musa D, Schulz R, Harris R, *et al.*: **Trust in the Health Care System and the Use of Preventive Health Services by Older Black and White Adults**. *Am J Public Health*. 2009; **99**(7): 1293–1299. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Bargain O, Aminjonov U: **Trust and Compliance to Public Health Policies in Times of Covid-19**. Social Science Research Network; 2020; Accessed July 27, 2020. [Reference Source](#)
19. Gille F, Smith S, Mays N: **Why public trust in health care systems matters and deserves greater research attention**. *J Health Serv Res Policy*. 2015; **20**(1): 62–64. [PubMed Abstract](#) | [Publisher Full Text](#)
20. Abelson J, Miller FA, Giacomini M: **What does it mean to trust a health system? A qualitative study of Canadian health care values**. *Health Policy*. 2009; **91**(1): 63–70. [PubMed Abstract](#) | [Publisher Full Text](#)
21. Thom DH, Hall MA, Pawlson LG: **Measuring Patients' Trust In Physicians When Assessing Quality Of Care**. *Health Aff (Millwood)*. 2004; **23**(4): 124–132. [PubMed Abstract](#) | [Publisher Full Text](#)
22. O'Malley AS, Sheppard VB, Schwartz M, *et al.*: **The role of trust in use of preventive services among low-income African-American women**. *Prev Med*. 2004; **38**(6): 777–785. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Pearson SD, Raeke LH: **Patients' trust in physicians: Many theories, few measures, and little data**. *J Gen Intern Med*. 2000; **15**(7): 509–513. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
24. Hall MA, Dugan E, Zheng B, *et al.*: **Trust in physicians and medical institutions: what is it, can it be measured, and does it matter?** *Milbank Q*. 2001; **79**(4): 613–639, v. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Middleton A, Milne R, Howard H, *et al.*: **Members of the public in the USA, UK, Canada and Australia expressing genetic exceptionalism say they are more willing to donate genomic data**. *Eur J Hum Genet*. 2020; **28**(4): 424–434. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Milne R, Morley KI, Howard H, *et al.*: **Trust in genomic data sharing among members of the general public in the UK, USA, Canada and Australia**. *Hum Genet*. 2019; **138**(11–12): 1237–1246. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Middleton A, Milne R, Thorogood A, *et al.*: **Attitudes of publics who are unwilling to donate DNA data for research**. *Eur J Med Genet*. 2019; **62**(5): 316–323. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Middleton A, Milne R, Almarri MA, *et al.*: **Global Public Perceptions of Genomic Data Sharing: What Shapes the Willingness to Donate DNA and Health Data?** *Am J Hum Genet*. 2020; **107**(4): 743–752. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Milne R, Morley KI, Almarri MA, *et al.*: **Demonstrating trustworthiness when collecting and sharing genomic data: public views across 22 countries**. *Genome Med*. Published online Under review.
30. Middleton A, Niemiec E, Prainsack B, *et al.*: **'Your DNA, Your Say': global survey gathering attitudes toward genomics: design, delivery and methods**. *Pers Med*. 2018; **15**(4): 311–318. [PubMed Abstract](#) | [Publisher Full Text](#)
31. Middleton A, Milne R, Morley KI, *et al.*: **Your DNA Your Say data file**. 2021. <http://www.doi.org/10.17605/OSF.IO/ZPFGM>
32. Luhmann N: **Social Systems**. Stanford University Press; 1995. [Reference Source](#)
33. Calnan MW, Sanford E: **Public trust in health care: the system or the doctor?** *Qual Saf Health Care*. 2004; **13**(2): 92–97. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Standing M, Hampson E: **Genomics in the UK: An Industry Study for the Office of Life Sciences**. 2015; 36. Accessed April 1, 2021. [Reference Source](#)
35. Baier A: **Trust and Antitrust**. *Ethics*. 1986; **96**(2): 231–260. [Reference Source](#)
36. Critchley C, Nicol D, Otlowski M: **The impact of commercialisation and genetic data sharing arrangements on public trust and the intention to participate in biobank research**. *Public Health Genomics*. 2015; **18**(3): 160–172. [PubMed Abstract](#) | [Publisher Full Text](#)
37. Nicol D, Critchley C, McWhirter R, *et al.*: **Understanding public reactions to commercialization of biobanks and use of biobank resources**. *Soc Sci Med*. 2016; **162**: 79–87. [PubMed Abstract](#) | [Publisher Full Text](#)
38. World Economic Forum: **Genomic Data Policy Framework and Ethical Tensions**. World Economic Forum; 2020. [Reference Source](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 28 June 2021

<https://doi.org/10.21956/wellcomeopenres.18566.r44006>

© 2021 Machirori M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mavis Machirori

Ada Lovelace Institute, London, UK

This is an important area of research as noted by the recent and numerous incidents where issues of public trust have been raised. The paper is engaging and provides important points to reflect on for all those embarking on genomic medicine. Importantly, the role of public engagement in genomics is a key conclusion. The following are some minor points to address:

- Typo in Aim 2 (engaging the public in genomic medicine).
- Regarding trust in any domestic/international doctor – would it be possible to critique some of the issues around trying to measure trust with questions such as any domestic doctor/international doctor across the likelihood of people actually accessing said doctors e.g. how likely is it that people in the UK used or accessed other domestic or international doctors to make this question meaningful, rather than hypothetical? Are there any explanations why these differences may exist between the UK and Canada, additionally?
- If I understand correctly, while more UK participants trusted domestic doctors, in fact, their willingness to donate by this factor was less than the Canadian participants. Does this change the significance attributed to the chi square figures given in Table 2?
- If it is the convention of this journal, then the pre-set level of p-values that were used to calculate significance should also be added for completeness.
- I think the N and n are reversed? N is usually for population and n for sample size, and if I understand, n/N is the sample responding in a certain way out of the entire study sample (e.g. Table 4 ages).
- While not the focus of this paper, could authors comment on the potential limitations of pursuing or implementing genomic medicine especially of personalization, regarding unequal benefits that may arise (e.g. homogenous data sets; donating data does not mean reaping benefits). This is so that any initiatives for public engagement with genomics must also be honest about the potential limitations of genomic medicine as it currently stands.

- One question around the demographics which is alluded to but not explored further is the potential of demographic differences. If this is not reported elsewhere, it will be helpful to understand any differences in the populations responding to the questionnaire to further provide recommendations of tailored trust-increasing interventions. This is especially important given different sections of the community will have different interactions and reasons for trusting. Without this, there will be some normative assumptions about a fairly distributed health care system and the amount of trust directed at the system by different sections of the community.
- Is there anything in the role of government that may lead to lowered trust (e.g. by age also)? While some UK examples are given, there is not much on the Canadian perspective.
- Finally, as part of the recommendations, it would be helpful to explain a little more about what a social license in this area might look like, or what conditions might help it along.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Diversity of data sets, genomics, data sharing, data governance, engagement

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Reviewer Report 18 June 2021

<https://doi.org/10.21956/wellcomeopenres.18566.r44003>

© 2021 Blasimme A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alessandro Blasimme

Health Ethics and Policy Lab, Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerland

The paper reports on the findings of the "Your DNA, your say" (YDYS) study on the public's attitudes towards sharing DNA data (Canada and UK). The topic is relevant to current debates about data sharing, in bioethics and beyond.

The paper is based on sound empirical methods, presents interesting interpretations of the findings and offers a valuable contribution to the debate.

My only suggestions are:

- To clarify whether DNA data sharing is discussed in the context of research (as it looks like) as opposed to public health and clinical use.
- To clarify whether participants were asked to express their views in relation to domestic as opposed to international data sharing.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Ethics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 25 Jun 2021

Sarah Savić-Kallesøe, University of Cambridge, Cambridge, UK

Thank you, Dr. Blasimme, for your time and expertise during this review. Your feedback has been reviewed and integrated into the newest version of the manuscript, including:

- clarification of the domestic, rather than international, nature of data sharing (discussion); and
- clarification of the research, rather than clinical, purposes of genomic data sharing within the context of this paper.

Thank you, again, for your help.

Competing Interests: No competing interests were disclosed.

Reviewer Report 10 June 2021

<https://doi.org/10.21956/wellcomeopenres.18566.r44004>

© 2021 Horn R. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ruth Horn

The Ethox Centre and Wellcome Centre for Ethics and Humanities, Nuffield Department of Population Health, University of Oxford, Oxford, UK

This paper makes an important contribution to the understanding of ethical, social and policy issues around genomic medicine by exploring which specific social actors (doctors, researchers and governments) are the most trustworthy and influential to engage the public in genomic medicine. Using data from the “Your DNA, Your Say” study, this paper focuses on the UK and Canada. Non-profit researchers, domestic doctors, and personal doctors were identified to be the most influential and trustworthy social actors in Canada and the UK.

The authors include links to the database, however, I was unable to open these as the link seemed to be invalid. Maybe the authors could check the link again.

I have a few minor comments, which, I hope, may help the authors to specify a few more details:

- The reasons the authors provide as to why they focus on the UK and Canada could be further developed. The authors state that they focus on them because of both having comparable universal health care systems, participating in the YDYS study and being Anglo-Saxon countries. These characteristics also apply to other countries and the particularities of why to focus on the UK and Canada could be further developed.
- Furthermore, the specific role of the NHS with regard to public trust in the UK context could be emphasised in the paper (see reports and surveys from the King's Fund).
- Social actors are defined in the paper as doctors, researchers and governments. Maybe the

authors could give a more precise definition of what it means to be a social actor, and why they chose to limit their discussion on doctors, researchers and governments.

- The use of the definition of 'Anglo-Saxon countries' is somehow problematic as US and Canadian populations cannot be considered as predominately 'white Saxons'. 'Anglo-American countries' or 'Anglo countries' may be more appropriate.
- P. 8 The discussion of public trust towards non-profit versus commercial researchers could be elaborated a little more, and further literature discussing these differences with regard to trust may be added.
- P.9 In the conclusion, the authors state: 'Both countries could gain from involving non-profit researchers, as trust in them is the most strongly associated with willingness to donate in both countries.' The authors could add a more explicit statement about what this would mean for public engagement activities, namely the importance of involving non-profit researchers in the public engagement.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: ethical issues with regard to the implementation of genomic medicine in different socio-cultural contexts

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 25 Jun 2021

Sarah Savić-Kallesøe, University of Cambridge, Cambridge, UK

Thank you Dr. Horn for your time and expertise. Your feedback has been reviewed and integrated into the newest version of the manuscript, including:

- updating "Anglo-Saxon" countries to "Anglo" countries (introduction);
- providing further context of the public's support of the UK NHS (using the King's Fund 2019 survey) (discussion);
- clarification of social actors (introduction); and
- elaboration of the role of for-profit researchers (discussion).

Thank you, again, for your help.

Competing Interests: No competing interests were disclosed.